FURI | Spring 2019

Optimizing Recombinant Protein Production for Domain Antibodies: Proof-of-Concept

Health icon, disabled. A red heart with a cardiac rhythm running through it.

Recent studies in traumatic brain injury (TBI) have found a temporal window where nanometer scale therapeutics can cross the blood-brain barrier into the parenchyma. Development of recombinant antibody production is attractive due to its wide range of biological applications in diagnostic and therapeutic use. However, the production pipeline for high yield, purified, and consistent bioactive recombinant proteins remains a major obstacle. This project aims to optimize this methodology and evaluate the potential to use Brevibacillus host to produce biologically active domain antibody proteins for future use in nanoparticle therapeutics.